Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Ipilimumab + Pembrolizumab in Melanoma Brain Metastases
NCT03873818Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2019
- Primary completion
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab and pembrolizumab in melanoma, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Clinical Benefit Rate in PD-1 naive Patients at 2 years. Started Feb 2019; status: completed.
02
Drugs
ipilimumabpembrolizumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03873818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873818.